About
Science & Epigenetics
Programs
Newsroom
Contact
Connect
Email
info@zenithepigenetics.com
Call
1 (587) 390-7865
Share
FAQ
Newsroom
News Releases
Presentations & Events
SEDAR Filings
News Releases
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
Zenith Epigenetics Announces Initiation of a Phase 2b Triple Negative Breast Cancer (TNBC) Clinical Trial
May 10, 2022
Zenith Epigenetics Announces Dosing of First Cancer Patient with a Combination of ZEN-3694 + Bristol Myers Squibb’s Immune Checkpoint Inhibitor OPDIVO
February 22, 2022
Zenith Epigenetics Announces Appointment to Board of Directors and Provides Clinical Update
January 31, 2022
© 2022 zenithepigenetics |
Legal
|
Privacy